Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ruboxistaurin (Eli Lilly).

Glen D Wheeler1

  • 1102-711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada. editor@greyowltutor.com

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed
Summary
This summary is machine-generated.

Eli Lilly is developing ruboxistaurin, a protein kinase C (PKC)-b inhibitor, for treating complications of diabetes. This novel macrocycle compound shows potential for diabetic retinopathy, neuropathy, and macular edema.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Ophthalmology
  • Neurology

Background:

  • Diabetic complications like retinopathy, neuropathy, and macular edema pose significant health challenges.
  • Protein kinase C beta (PKC-b) is implicated in the pathogenesis of these diabetic microvascular complications.

Purpose of the Study:

  • To evaluate ruboxistaurin, a novel protein kinase C (PKC)-b inhibitor, as a potential therapeutic agent.
  • To explore the efficacy of ruboxistaurin in treating diabetic retinopathy, diabetic peripheral neuropathy, and macular edema.

Main Methods:

  • Development of ruboxistaurin, a lead compound from a series of 14-membered macrocycles.
  • Preclinical and/or clinical investigations into the pharmacological effects of ruboxistaurin.

Main Results:

Related Experiment Videos

  • Ruboxistaurin demonstrates inhibitory activity against protein kinase C beta (PKC-b).
  • The compound is under investigation for its potential to mitigate or reverse diabetic microvascular damage.

Conclusions:

  • Ruboxistaurin represents a promising therapeutic candidate for managing diabetic microvascular complications.
  • Targeting protein kinase C beta (PKC-b) may offer a viable strategy for treating diabetic retinopathy, neuropathy, and macular edema.